Study on serological screening and pregnancy outcome od Down syndrome during mid-term pregnancy

Objective To explore the clinical value of Down's Screening in the middle pregnancy to antenatal diagnosis and congenital birth defect. Methods Serum AFP,free-β-HCG and u E3 level of 2386 pregnant women( 14 ~ 20 + 6) from July 2010 to April 2013 in our hospital were detected by fully automatic chemiluminescence method. The value of serum markers combined with the maternal age,gestational age,weight and other index were conduct a comprehensive analysis by Multicalc software to calculate Down,s syndrome risk.For these high risk gravida,conduct fetal karyotype analysis and continue to track the fetal and maternal outcomes. Results There were 101 cases of high risk pregnant women of 2386 pregnant women and the positive rate is 4. 23%( 101 /2386). 5 cases of fetal chromosome abnormalities in 89 pregnant women who received prenatal diagnosis of amniotic fluid. Among the 5 fetal chromosome abnormalities,there were 1 case of Down 's syndrome,2 cases of 18-trisomy,1 cases of Tumer ˊ s syndrome. The adverse pregnancy outcomes in the high risk and low risk group of Down ˊ s screening were 28. 71% and 7. 61%,showing significant difference( χ2=55. 31,P 0. 05). Conclusions Down,s Screening in the middle pregnancy is an effective tool for predicting abnormal and adverse pregnancy outcomes. Combination of amniotic fluid prenatal diagnosis has an important clinical value for prevent adverse pregnancy.